News Headlines Article

F.D.A. Declines to Approve Diet Drug
New York Times

The Food and Drug Administration has declined to approve yet another prescription diet pill, saying the developer must first do a long-term study to demonstrate that the drug does not raise the risk of heart attacks. The failure of the drug, known as Contrave, to gain approval was not totally unexpected. But the requirement that its developer, Orexigen Therapeutics, first do a study to rule out cardiovascular problems was somewhat unexpected and could pose a significant obstacle to approval.